ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Clinical trials for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for AML patients: study tests better drug to keep leukemia away after transplant
Disease control Recruiting nowThis study tests whether a newer drug, gilteritinib, works better than the current standard, sorafenib, to prevent leukemia from coming back after a stem cell transplant. About 594 adults and teens with a specific genetic mutation (FLT3-ITD) will be randomly assigned to take one …
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 26, 2026 10:11 UTC
-
New drug aims to keep leukemia away after transplant
Disease control Recruiting nowThis study tests whether a drug called chidamide can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 134 adults with high-risk AML who are in remission after transplant will either receive chidamide or be observed. The goal is to see…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 20, 2026 11:55 UTC